NCT07108907 (ORANGE-TEER) is a clinical trial in Mitral Regurgitation, sponsored by Abby Geerlings.

Who is sponsoring NCT07108907?

NCT07108907 is sponsored by Abby Geerlings.

What condition does NCT07108907 study?

NCT07108907 studies Mitral Regurgitation.

Is NCT07108907 still recruiting?

NCT07108907 is currently recruiting now. Last updated 7 August 2025.

Last reviewed 2025-08-07 · How we verify

NCT07108907: ORANGE-TEER

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Outcome Registry and Assessment of New Edge-to-Edge Repair

Recruiting now Last updated 7 August 2025

What this trial tests

trial in Mitral Regurgitation in 300 participants. Currently enrolling.

Timeline

10 July 2025

Primary endpoint
1 January 2030

1 January 2035

Quick facts

Lead sponsor	Abby Geerlings
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	300
Start date	10 July 2025
Primary completion	1 January 2030
Estimated completion	1 January 2035
Sites	1 location across Netherlands

Conditions studied

Mitral Regurgitation — all drugs for Mitral Regurgitation →

Sponsor

Abby Geerlings

Who can join

Eligibility, any sex, with Mitral Regurgitation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational study is to learn about the long-term effects of Edge-tot-edge repair of all the patients of AmsterdamUMC, to treat their Mitral regurgitation (MR). The main question it aims to answer is: The patient selection process could be optimized. Participants are already receiving edge-to-edge repair as part of their standard medical care and will additionally complete quality-of-life survey questions.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Mitral Regurgitation

Currently open trials in the same condition.

NCT07450911 — A Clinical Study Evaluating the Replacement of the Native Mitral Valve Using the ReValve System · Phase 1 · recruiting
NCT07366723 — The Role of cardIac magNeTic rEsonance in surGical Decision Making in Patients With Severe pRimAry miTral rEgurgitation · NA · active not recruiting
NCT07007143 — STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication fo · Phase 4 · recruiting
NCT06901466 — STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients With an Indication for O · Phase 4 · recruiting
NCT07055919 — Structural Heart Surgery Assist System for Transcatheter Mitral Valve Edge-to-Edge Repair (TEER). · NA · recruiting

Other Abby Geerlings trials

Trials by the same sponsor.

NCT07263659 — Virtual Reality Reduces Pre-Procedural Anxiety in TEER Patients, But Timing Seems Crucial · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07108907 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Abby Geerlings
Last refreshed: 7 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07108907.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing